epigenetics
OncoDiag Taking Aim at Broader Adoption of Molecular Multiplex Test for Bladder Cancer Recurrence
Premium
On the back of a recently announced $3 million in funding, the firm has begun marketing its Urodiag kit to urologists throughout Europe.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
Delfi Diagnostics Starts Prospective Lung Cancer Screening Trial
The company is planning to commercialize its cancer early detection technology initially in lung cancer and is working with NYU researchers to explore future expansions.
DARPA program managers said they are developing different testing modalities that are crucially linked in their objective to facilitate more comprehensive and faster testing.
The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.